<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04550962</url>
  </required_header>
  <id_info>
    <org_study_id>OBS16688</org_study_id>
    <nct_id>NCT04550962</nct_id>
  </id_info>
  <brief_title>Description of Characteristics, Such as Age, Previous and Concurrent Treatments, Associated Diseases, of Patients With Asthma Treated With Dupilumab (DUPIXENT)</brief_title>
  <acronym>REVEAL</acronym>
  <official_title>PRospEctiVe charactErization of Asthma Patients Treated With DupilumAb in reaL World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      The primary objective of the study is to characterize patients initiating DUPIXENT for asthma&#xD;
      in a real-world setting, with respect to their medical history, including asthma history and&#xD;
      asthma treatment history, socio-demographic, biomarkers (including Fractional exhaled nitric&#xD;
      oxide [FeNO]), and concomitant treatments for asthma.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      The secondary objectives of the study are:&#xD;
&#xD;
        -  To characterize real-world use patterns of DUPIXENT for asthma (eg, most commonly used&#xD;
           regimens, reason for initiation of new asthma treatments, concomitant therapies,&#xD;
           treatment durations, and reasons for discontinuation and/or switching)&#xD;
&#xD;
        -  To assess the effectiveness of DUPIXENT in asthma patients in a real world setting (lung&#xD;
           function improvement, exacerbation rate, asthma control)&#xD;
&#xD;
        -  To assess comorbid type 2 conditions (atopic/allergic) and patterns of use and effects&#xD;
           of treatment in comorbid conditions in asthma patients treated with Dupixent&#xD;
&#xD;
        -  To collect data on HealthCare Resource Utilization (HCRU)&#xD;
&#xD;
        -  To collect safety data on study participants in the real-world setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient will be followed during 36 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2, 2020</start_date>
  <completion_date type="Anticipated">May 2026</completion_date>
  <primary_completion_date type="Anticipated">May 2026</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>36 Months</target_duration>
  <primary_outcome>
    <measure>Baseline Characteristics: Socio-demographics</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Characteristics: Medical history</measure>
    <time_frame>At baseline</time_frame>
    <description>Including asthma history and asthma treatment history.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Characteristics: Disease characteristics</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Baseline Characteristics: Concomitant treatments for asthma</measure>
    <time_frame>At baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dupixent and other asthma treatment use patterns</measure>
    <time_frame>Baseline to Month 54</time_frame>
    <description>Including doses and dose frequency, treatment duration, asthma treatment associations (eg, Dupixent monotherapy, Dupixent + inhaled corticosteroids (ICS), Dupixent + ICS + additional controllers, oral corticosteroid (OCS) burst), and reasons for initiation and for discontinuation/switching.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung function</measure>
    <time_frame>Baseline to Month 54</time_frame>
    <description>Pre and post bronchodilator (BD) forced expiratory volume in 1 second (FEV1) over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized exacerbation rate</measure>
    <time_frame>Baseline to Month 54</time_frame>
    <description>An Exacerbation event is defined as a deterioration of asthma requiring:&#xD;
Use of systemic corticosteroids for â‰¥3 days; or&#xD;
Hospitalization or emergency room visit because of asthma, requiring systemic corticosteroids.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient reported outcomes</measure>
    <time_frame>Baseline to Month 54</time_frame>
    <description>For asthma and type 2 comorbidities over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Healthcare Resource Utilization</measure>
    <time_frame>Baseline to Month 54</time_frame>
    <description>The Healthcare Resource Utilization (HCRU) is a questionnaire filled out by the participating site at baseline and at clinical visits (scheduled and unscheduled) throughout the study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AE) and serious adverse events (SAE)</measure>
    <time_frame>Baseline to Month 54</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Participants with asthma</arm_group_label>
    <description>Eligible participants are initiating treatment with Dupixent for asthma according to the prescribing information in effect in each country</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dupilumab SAR231893</intervention_name>
    <description>Pharmaceutical form:solution Route of administration: subcutaneous&#xD;
Dose regimen:</description>
    <arm_group_label>Participants with asthma</arm_group_label>
    <other_name>Dupixent</other_name>
  </intervention>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      max 1000 characters&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with asthma initiating DUPIXENT for their asthma according to the prescribing&#xD;
        information in effect in each country.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        - Male or female, 12 years or older Initiating treatment with Dupixent for asthma according&#xD;
        to the country-specific prescribing information Willing and able to comply with the&#xD;
        required clinic visits, study procedures and assessments.&#xD;
&#xD;
        Provided signed informed consent&#xD;
&#xD;
        - Most important exclusion criteria for potential participants Patients who have a&#xD;
        contraindication to Dupixent according to the country-specific prescribing information&#xD;
        Treatment with Dupixent within 6 months before the baseline visit. Note: for patients who&#xD;
        have been treated previously with DUPIXENT a washout period of 6 months is required before&#xD;
        Visit 1.&#xD;
&#xD;
        Any condition that, in the opinion of the Investigator, may interfere with patient's&#xD;
        ability to participate in the study, such as short life expectancy, substance abuse, severe&#xD;
        cognitive impairment, or other comorbidities that can predictably prevent the patient from&#xD;
        adequately completing the schedule of visits and assessments Patients currently&#xD;
        participating in any interventional clinical trial which modifies patient care.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 4140001</name>
      <address>
        <city>Kuwait</city>
        <zip>00000</zip>
        <country>Kuwait</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430005</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454091</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430007</name>
      <address>
        <city>Moscow</city>
        <zip>105077</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430004</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430006</name>
      <address>
        <city>Rostov-On-Don</city>
        <zip>344012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430008</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6430002</name>
      <address>
        <city>Stavropol</city>
        <zip>355020</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6820004</name>
      <address>
        <city>Makkah</city>
        <zip>24246</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 6820002</name>
      <address>
        <city>Riyadh</city>
        <zip>11525</zip>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7840005</name>
      <address>
        <city>Ras Al Khaimah</city>
        <zip>00000</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7840004</name>
      <address>
        <city>Sharjah</city>
        <zip>00000</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 7840002</name>
      <address>
        <city>Sharjah</city>
        <zip>3499</zip>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Kuwait</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>September 9, 2020</study_first_submitted>
  <study_first_submitted_qc>September 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>April 2, 2021</last_update_submitted>
  <last_update_submitted_qc>April 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

